Skip to main content

Central Venous Pressure

0
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Compremium
CompremiumSwitzerland - Bern
1 program
CPMX2N/A1 trial
Active Trials
NCT06885073Recruiting100Est. Mar 2026
NeuroDx Development
1 program
Non-Invasive CVP vs Standard CVPN/A1 trial
Active Trials
NCT03705299Completed40Est. Apr 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
CompremiumCPMX2
NeuroDx DevelopmentNon-Invasive CVP vs Standard CVP

Clinical Trials (2)

Total enrollment: 140 patients across 2 trials

Non-invasive Central Venous Pressure Estimation in Pediatric Patients

Start: Mar 2025Est. completion: Mar 2026100 patients
N/ARecruiting
NCT03705299NeuroDx DevelopmentNon-Invasive CVP vs Standard CVP

Non-Invasive CVP Method to Standard CVP Method

Start: Nov 2012Est. completion: Apr 201840 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 140 patients
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.